Ondine Biomedical (FRA:VF5) Net Margin %: -952.26% (As of Dec. 2024)


FRA:VF5 Ondine Biomedical Inc FRA:VF5
47 GF Score
Price €0.15
View Full Analysis

What is Ondine Biomedical Net Margin %?

Ondine Biomedical FRA:VF5 47 Net Margin % is -952.26% as of Dec. 2024. GuruFocus rates FRA:VF5 with a GF Score™ of 47/100.

Net margin is calculated as Net Income divided by its Revenue. Ondine Biomedical's Net Income for the six months ended in Dec. 2024 was €-7.60 Mil. Ondine Biomedical's Revenue for the six months ended in Dec. 2024 was €0.80 Mil. Therefore, Ondine Biomedical's net margin for the quarter that ended in Dec. 2024 was -952.26%.

The historical rank and industry rank for Ondine Biomedical's Net Margin % or its related term are showing as below:


FRA:VF5's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.33
* Ranked among companies with meaningful Net Margin % only.

Ondine Biomedical  (FRA:VF5) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Ondine Biomedical Net Margin % Related Terms

Ondine Biomedical Net Margin % Historical Data

* Premium members only.

The historical data trend for Ondine Biomedical's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ondine Biomedical Net Margin % Chart

Ondine Biomedical Annual Data
Trend Dec09 Dec10 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -908.79 -1,949.83 -3,038.60 -1,198.42 -932.41

Ondine Biomedical Semi-Annual Data
Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,875.86 -1,847.81 -839.81 -904.12 -952.26

FRA:VF5 vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Ondine Biomedical's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ondine Biomedical Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ondine Biomedical's Net Margin % distribution charts can be found below:

* The bar in red indicates where Ondine Biomedical's Net Margin % falls into.


FRA:VF5
47GF Score
Ondine Biomedical Inc FRA:VF5
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ondine Biomedical Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Ondine Biomedical's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-12.802/1.373
=-932.41 %

Ondine Biomedical's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin=Net Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-7.599/0.798
=-952.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -952.26% mean?
Ondine Biomedical (FRA:VF5) has a Net Margin % of -952.26% as of Dec. 2024. Net margin is the ratio of total net income to net sales. View historical data on Ondine Biomedical and its competitors.
Is Ondine Biomedical's Net Margin % too high?
Ondine Biomedical's current Net Margin % is -952.26%. Overall, Ondine Biomedical has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Ondine Biomedical's Net Margin % compare to VRTX and REGN?
Ondine Biomedical's Net Margin % of -952.26% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Ondine Biomedical and its competitors. Ondine Biomedical's current Net Margin % is -952.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ondine Biomedical stock overvalued right now?
Ondine Biomedical (FRA:VF5) has a current Net Margin % of -952.26%. The current Net Margin % is -952.26%. Ondine Biomedical's overall GF Score™ is 47/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Ondine Biomedical (FRA:VF5), the current Net Margin % is -952.26% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ondine Biomedical Business Description

Address 1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
47GF Score

Get the complete analysis for FRA:VF5

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price